Metraipolis › archive › dc_3bc4692bd451
Pembrolizumab-Induced Capillary Leak Syndrome: A Rare but Life-Threatening Immune-Related Adverse Event — Europe PMC PMID:41281016
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/41281016
- DOI
- 10.7759/cureus.95038
- License (as archived)
- solo-consultazione
- Archived
- 2026-11-09T04:42:00.055Z
- SHA-256 of the archived text
ffdf9efd093f0744eb40a127fc1bf1f223f7ba4e3174f4ba4bf177435a647dfc- Stable URL of this page
https://metraipolis.com/documento/dc_3bc4692bd451
How to cite
Pembrolizumab-Induced Capillary Leak Syndrome: A Rare but Life-Threatening Immune-Related Adverse Event — Europe PMC PMID:41281016 — Europe PMC (en), https://europepmc.org/article/MED/41281016 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_3bc4692bd451 (Metraipolis archive dc_3bc4692bd451, sha256 ffdf9efd093f0744eb40a127fc1bf1f223f7ba4e3174f4ba4bf177435a647dfc)
BibTeX
@misc{dc3bc4692bd451,
title = {Pembrolizumab-Induced Capillary Leak Syndrome: A Rare but Life-Threatening Immune-Related Adverse Event — Europe PMC PMID:41281016},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/41281016},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_3bc4692bd451; sha256 ffdf9efd093f0744eb40a127fc1bf1f223f7ba4e3174f4ba4bf177435a647dfc},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41281016. Agents can read the archived copy with the MCP tool read_document.